Feb 12, 2026 4:15pm EST Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Feb 06, 2026 9:00am EST Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Nov 13, 2025 4:05pm EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Sep 29, 2025 4:05pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
Sep 25, 2025 7:30am EDT Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
Sep 12, 2025 7:30am EDT Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
Jul 23, 2025 8:00am EDT Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
